سعر ليندينت 0.03/0.075مجم 21 قرص 2026

Combined oral contraceptive coated tablets containing ethinylestradiol 0.03 mg and gestodene 0.075 mg, 21 tablets per cycle.

• Oral contraception.Population: Women of reproductive ageelectronic medicines compendium (eMC)

• Common (at least 1 in 100): nausea, abdominal pain, weight increase, headache, depressed mood or mood changes, breast pain and tenderness. Serious: venous and arterial thromboembolic events.International label, equivalent formulation · electronic medicines compendium (eMC)

• Presence or risk of venous or arterial thromboembolism (current or past VTE/ATE, known thrombophilia, major surgery with prolonged immobilisation, multiple risk factors); history of migraine with focal neurological symptoms; severe hepatic disease until liver function normalises; past or present liver tumours; known or suspected sex-steroid-influenced malignancies (e.g. breast cancer); undiagnosed vaginal bleeding; hypersensitivity to the active substances or excipients.International label, equivalent formulation · electronic medicines compendium (eMC)
• Concomitant use with medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir, glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir.International label, equivalent formulation · electronic medicines compendium (eMC)

• Combined hormonal contraceptives increase the risk of venous thromboembolism; about 9 to 12 of 10,000 women using a gestodene-containing CHC develop VTE per year, compared with about 6 for levonorgestrel-containing CHCs and about 2 in non-users.International label, equivalent formulation · electronic medicines compendium (eMC)
• Increased risk of arterial thromboembolism (myocardial infarction, stroke), particularly in women over 35 who smoke (advise not to smoke), and with hypertension, obesity or migraine.International label, equivalent formulation · electronic medicines compendium (eMC)
• Other warnings: blood pressure may rise (stop if sustained hypertension); depressed mood and depression, including suicidal behaviour, have been reported; slightly increased relative risk of breast cancer diagnosis (RR 1.24) in current users; rare benign and very rare malignant liver tumours.International label, equivalent formulation · electronic medicines compendium (eMC)

• Hepatic enzyme inducers (e.g. barbiturates, phenytoin, carbamazepine, oxcarbazepine, topiramate, primidone, rifampicin, griseofulvin, St John's wort, ritonavir, nelfinavir, nevirapine)Enzyme inducers can reduce contraceptive efficacy; use a barrier method during the inducer and for 28 days after stopping it, or choose another contraceptive for long-term use.electronic medicines compendium (eMC)
• Strong and moderate CYP3A4 inhibitors (e.g. azole antifungals, verapamil, macrolides, diltiazem, grapefruit juice)May increase plasma concentrations of the oestrogen, the progestogen or both.electronic medicines compendium (eMC)
• LamotrigineCombined hormonal contraceptives can significantly decrease lamotrigine plasma concentrations, which may reduce seizure control.electronic medicines compendium (eMC)

• Not indicated during pregnancy; if pregnancy occurs during use, stop taking the tablets. Extensive epidemiological studies have found neither an increased risk of birth defects in children born to women who used COCs before pregnancy nor a teratogenic effect when taken inadvertently in early pregnancy.International label, equivalent formulation · electronic medicines compendium (eMC)
• Combined oral contraceptives may reduce the quantity and change the composition of breast milk and small amounts of the steroids may be excreted in milk; use is generally not recommended until weaning, and another method of contraception should be used.International label, equivalent formulation · electronic medicines compendium (eMC)

English text not available for this section.